Vivus Poised To Enter Phase III With Obesity Candidate Qnexa
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm touts safety advantage of experimental phentermine/topiramate combination therapy.
You may also be interested in...
Vivus’ Qnexa Works “Surprisingly” Well In Diabetes
Obesity drug could double its market opportunity, analysts say.
Vivus’ Qnexa Works “Surprisingly” Well In Diabetes
Obesity drug could double its market opportunity, analysts say.
Arena’s Lorcaserin Can Continue To Bloom In Phase III Obesity Trial
Safety monitoring board review of echocardiographic data gives firm a green light to continue with pivotal trial.